Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alpha Tau Medical Ltd. - Ordinary Shares
(NQ:
DRTS
)
4.950
-0.080 (-1.59%)
Streaming Delayed Price
Updated: 11:01 AM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alpha Tau Medical Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
In today's session, these stocks are experiencing unusual volume.
↗
December 11, 2025
In today's session, these stocks are experiencing unusual volume.
Via
Chartmill
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
December 09, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
December 04, 2025
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Expert Ratings for Alpha Tau Medical
↗
December 15, 2023
Via
Benzinga
Analyst Ratings for Alpha Tau Medical
↗
November 17, 2023
Via
Benzinga
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
December 02, 2025
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer -
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 22, 2025
Via
Benzinga
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
October 21, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
September 02, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish
↗
May 20, 2025
The company’s stock surged to a three-month high following its Q1 report, progress in FDA-approved clinical trials, and a recent capital raise.
Via
Stocktwits
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
April 28, 2025
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ...
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
April 02, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
March 18, 2025
Via
ACCESS Newswire
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
February 24, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
February 03, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
January 27, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
December 18, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
December 17, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
October 21, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Treats First Patient with Recurrent Lung Cancer
October 10, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
September 20, 2024
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population -
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024
↗
August 14, 2024
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
June 25, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024
↗
May 20, 2024
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
May 13, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023
↗
March 07, 2024
DRTS stock results show that Alpha Tau Medical beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 10, 2024
Via
Benzinga
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
November 28, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
November 20, 2023
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
